4 results match your criteria: "Paris University (Paris-Diderot)[Affiliation]"
Mucosal immunity to SARS-CoV-2: a clinically relevant key to deciphering natural and vaccine-induced defences.
Clin Microbiol Infect
December 2021
Faculty of Medicine, Paris University (Paris-Diderot), 75010, Paris, France. Electronic address:
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.
Blood Adv
November 2020
Department of Hemato-Oncology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Chimeric antigen receptor (CAR) T-cell therapy has emerged as an option for relapsed/refractory aggressive B-cell lymphomas that have failed 2 lines of therapy. Failures usually occur early after infusion. The purpose of our study was to identify factors that may predict failure, particularly early progression (EP), within the first month after infusion.
View Article and Find Full Text PDFRole of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation.
J Clin Oncol
February 2019
1 Charité - University Medical Center Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
Purpose: Clonal hematopoiesis of indeterminate potential (CHIP) occurs in the blood of approximately 20% of older persons. CHIP is linked to an increased risk of hematologic malignancies and of all-cause mortality; thus, the eligibility of stem-cell donors with CHIP is questionable. We comprehensively investigated how donor CHIP affects outcome of allogeneic hematopoietic stem-cell transplantation (HSCT).
View Article and Find Full Text PDFAPRIL levels are associated with disease activity in human chronic graft-versus-host disease.
Haematologica
July 2016
INSERM and UMRS 976, Laboratory of Onco dermatology, Immunology, and Cutaneous Stem cells, F-75739 Paris University Paris Diderot, Sorbonne Paris Cité Dermatology Department, Saint-Louis Hospital, Paris.